Explore the potential of invariant natural killer T (iNKT) cells in developing "off-the-shelf" cancer therapies in this 34-minute webinar presented by Dr. Lili Yang, Associate Professor at UCLA. Learn about the advantages of iNKT cells as ideal carriers for allogeneic cell therapy, their ability to target cancers without graft-versus-host disease risk, and the latest advancements in cell-based immunotherapy. Gain insights into the development of large-scale, readily distributable cell products for treating cancer patients. Watch the presentation on YouTube or the Labroots website and earn PACE credits upon completion.
Harnessing iNKT Cells for Off-The-Shelf Cancer Therapy
Overview
Syllabus
Harnessing iNKT Cells for "Off-The-Shelf" Cancer Therapy
Taught by
Labroots
Related Courses
-
Reprogramming Natural Killer Cells for Cancer Immunotherapy
-
Catapult Your Cell Therapy Research Into the Clinic: CAR NK Cells and Tregs
-
Selective Depletion of CD45RA Expressing Cells to Enrich Antigen-Specific T-Cells for Immunotherapy
-
The Promise and Limits of Cancer Immunotherapy - TED
-
Cytokine Armored CAR NK Cell Therapy for Advanced Ovarian Cancer
-
Next Generation Genetic Discovery Systems in Human Immune Cells
